BioSpace Collaborative

Academic/Biomedical Research
News & Jobs
Biotechnology and Pharmaceutical Channel Medical Device and Diagnostics Channel Clinical Research Channel BioSpace Collaborative    Job Seekers:  Register | Login          Employers:  Register | Login  

NEWSLETTERS
Free Newsletters
Archive
My Subscriptions

NEWS
News by Subject
News by Disease
News by Date
PLoS
Search News
Post Your News
JoVE

CAREER NETWORK
Job Seeker Login
Most Recent Jobs
Search Jobs
Post Resume
Career Fairs
Career Resources
For Employers

HOTBEDS
Regional News
US & Canada
  Biotech Bay
  Biotech Beach
  Genetown
  Pharm Country
  BioCapital
  BioMidwest
  Bio NC
  BioForest
  Southern Pharm
  BioCanada East
  C2C Services & Suppliers™
Europe
Asia

DIVERSITY

PROFILES
Company Profiles

INTELLIGENCE
Research Store

INDUSTRY EVENTS
Research Events
Post an Event
RESOURCES
Real Estate
Business Opportunities

 News | News By Subject | News by Disease News By Date | Search News
Get Our Industry eNewsletter FREE email:    
   

Excelimmune, Inc. Raises $12 Million to Advance Infectious Disease Programs and Expand its Human Recombinant Polyclonal Antibody Platform into Additional Therapeutic Areas


12/20/2011 7:07:43 AM

WOBURN, Mass.--(BUSINESS WIRE)--Excelimmune, Inc. today announced that the company has raised $12 million from a private investor. Proceeds will be used by Excelimmune to develop its infectious disease programs, including Staphguard, a human recombinant polyclonal antibody (HRPA) candidate against methicillin-resistant Staphylococcus aureus (MRSA), and to expand its discovery programs to new disease targets beyond infectious diseases through its antibody screening technology.

“Novel treatments in nocosomial infections that can overcome treatment challenges such as resistance are urgently needed, and the continued financial support will enable us to advance our programs toward clinical trials,” said Quinton Zondervan, Chief Executive Officer or Excelimmune. “We believe HRPAs will provide a safer and more effective treatment option for nocosomial infectious compared to conventional anti-infective drugs. Beyond infectious diseases, HRPAs have broad potential across multiple therapeutic areas, for which we are pursuing partnerships. We are also expanding our personnel and pipeline to further exploit our technology’s potential.”

About Human Recombinant Polyclonal Antibodies

Human recombinant polyclonal antibodies are mixed populations of therapeutic antibodies that bind to multiple regions (epitopes) on a specific antigen or to multiple antigens (of bacteria, viruses and other microorganisms), in contrast to monoclonal antibodies, which only bind to one specific epitope. By binding to multiple regions, the polyclonal antibodies allow the body to fight off illness more readily. The antibodies are cloned from naturally occurring human antibodies in a laboratory and are then manufactured for human medical use.

About Excelimmune

Excelimmune, Inc. is a biopharmaceutical company specializing in the development of recombinant polyclonal antibodies to create novel therapies for treating disease in humans. Excelimmune’s antibody therapies harness the diversity and effectiveness of the human body’s adaptive immune system. The company is initially focusing on the treatment of infections caused by Staphylococcus aureus, including the drug resistant superbug, MRSA. This next generation technology is also believed to be applicable in the treatment of other pathogenic bacteria and viruses, disease causing proteins, and cancer. Excelimmune, founded in 2006, is a private company located in Woburn, Mass. www.excelimmune.com.

Contact:

Excelimmune:

Quinton Zondervan, 617-497-4303 x10

CEO

or

Media:

MacDougall Biomedical Communications

Kari Watson, 781-235-3060

kwatson@macbiocom.com


Read at BioSpace.com

   

ADD TO DEL.ICIO.US    ADD TO DIGG    ADD TO FURL    ADD TO STUMBLEUPON    ADD TO TECHNORATI FAVORITES
 

//-->